FDA Faces a Core Problem in Psychedelic Trials: Everyone Knows Who Got the Drug
In many studies, participants can tell when they received the active drug. That makes these trials functionally open label.
Read MoreB2B resources and operational guidance for ketamine and psychedelic clinic owners.
In many studies, participants can tell when they received the active drug. That makes these trials functionally open label.
Read More
Patients are asking AI tools for ketamine clinic recommendations — and most clinics are invisible. Here are the 6 ranking
Read More